Form 4: AEON Biopharma Director Eric Carter Granted Over 300,000 Restricted Stock Units

AEON Biopharma, Inc. Director Eric G. Carter has been granted 308,641 Restricted Stock Units (RSUs) as part of his compensation, vesting fully on May 21, 2026.

Summary

• Eric G. Carter, a Director of AEON Biopharma, Inc. (AEON), was granted 308,641 Restricted Stock Units (RSUs).
• The transaction date for this grant was May 21, 2025.
• Each RSU will be settled in cash based on the fair market value of the Issuer's Class A Common Stock on the applicable vesting date.
• All 308,641 RSUs are scheduled to vest in full on the one-year anniversary of the grant date, specifically May 21, 2026.
• Following this transaction, Eric G. Carter beneficially owns 308,641 Restricted Stock Units directly.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the RSU grant is a standard practice for incentivizing a director, aligning their interests with shareholders, and does not indicate any negative operational or financial issues. It reflects ongoing compensation practices.

Positives

• The grant of Restricted Stock Units aligns the director's interests with those of shareholders by tying a portion of his compensation to the company's future stock performance.
• Equity compensation is a standard practice for incentivizing key personnel and directors, reflecting a commitment to long-term value creation.

Future Outlook

The future outlook related to this filing primarily concerns the vesting of the 308,641 Restricted Stock Units on May 21, 2026, at which point they will be settled in cash based on the fair market value of AEON's Class A Common Stock.

Industry Context

The granting of Restricted Stock Units (RSUs) to directors is a common form of equity compensation across various industries, including biopharma, designed to attract, retain, and incentivize leadership by aligning their financial interests with the long-term performance of the company's stock.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of director compensation is a widely accepted and standard practice within the biotechnology and pharmaceutical industries, similar to compensation structures seen at companies like Amgen Inc. or Gilead Sciences, Inc., which frequently utilize equity grants to incentivize their leadership.
• The vesting schedule, a single cliff vest after one year, is a common approach for RSU grants to directors, providing a clear incentive for continued service and performance over the short to medium term.

Related Party Transactions

• The grant of 308,641 Restricted Stock Units to Eric G. Carter, a Director of AEON Biopharma, Inc., constitutes a related party transaction as it involves compensation from the company to an insider. This is a standard form of executive and director compensation.

Stakeholder Impact

• Shareholders: The RSU grant aims to align the director's financial interests with shareholder value creation, potentially leading to more focused long-term decision-making.
• Employees: While not directly impacting all employees, such compensation practices can set a precedent for equity-based incentives within the company.

Next Steps

• The Restricted Stock Units will vest on May 21, 2026.
• Upon vesting, the RSUs will be settled in cash based on the fair market value of AEON's Class A Common Stock.

Key Dates

Keywords

AEON Biopharma, Restricted Stock Units, RSU, Insider Transaction, Director Compensation, Equity Grant, Form 4, SEC Filing